← Scholar Rock overview

Scholar Rock vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Scholar Rock Holding Corp (SRRK)

Q3 2026
▲3

FDA Approves Scholar Rock's First SMA Drug; Analysts Split on What's Next

  • FDA approval of Isembyld (apitegromab) for SMA The FDA approved Isembyld, the first SMA drug that targets muscle directly, for patients 2 and older already on SMN2 therapy. This turns Scholar Rock into a commercial company with a U.S. launch underway, a major positive driver.

    This is the single biggest new event of the period and the main reason SRRK is moving.

  • Regulatory path cleared in U.S., Europe, Japan Scholar Rock removed a problem fill-finish plant from its application, kept its FDA decision date, and got Japan's OK that no extra trials are needed. Europe will be resubmitted. This lowers the risk of delays and opens more markets.

    It explains why the approval came through and how the company can sell the drug beyond the U.S.

  • Analyst downgrade and price-target split after approval Barclays downgraded SRRK to Equal Weight, saying the approval was already priced in and the non-SMA pipeline needs more proof. Other firms raised targets into the $70s-$80s. This tug-of-war explains recent share swings.

    It is the main counterweight to the good news and shows why the stock fell even after approval.

  • Commercial launch and pricing underway Isembyld is shipping, with a patient support program for insurance and infusions. Announced pricing slightly beat analyst estimates. Early sales execution will now drive the stock more than approval headlines.

    It shows the next phase for SRRK: turning approval into actual revenue.

August 2026
▲3

FDA Approves Scholar Rock's First SMA Drug; Analysts Split on What's Next

  • FDA approval of Isembyld (apitegromab) for SMA The FDA approved Isembyld, the first SMA drug that targets muscle directly, for patients 2 and older already on SMN2 therapy. This turns Scholar Rock into a commercial company with a U.S. launch underway, a major positive driver.

    This is the single biggest new event of the period and the main reason SRRK is moving.

  • Regulatory path cleared in U.S., Europe, Japan Scholar Rock removed a problem fill-finish plant from its application, kept its FDA decision date, and got Japan's OK that no extra trials are needed. Europe will be resubmitted. This lowers the risk of delays and opens more markets.

    It explains why the approval came through and how the company can sell the drug beyond the U.S.

  • Analyst downgrade and price-target split after approval Barclays downgraded SRRK to Equal Weight, saying the approval was already priced in and the non-SMA pipeline needs more proof. Other firms raised targets into the $70s-$80s. This tug-of-war explains recent share swings.

    It is the main counterweight to the good news and shows why the stock fell even after approval.

  • Commercial launch and pricing underway Isembyld is shipping, with a patient support program for insurance and infusions. Announced pricing slightly beat analyst estimates. Early sales execution will now drive the stock more than approval headlines.

    It shows the next phase for SRRK: turning approval into actual revenue.

Latest
▲3

FDA Approves Scholar Rock's First SMA Drug; Analysts Split on What's Next

  • FDA approval of Isembyld (apitegromab) for SMA The FDA approved Isembyld, the first SMA drug that targets muscle directly, for patients 2 and older already on SMN2 therapy. This turns Scholar Rock into a commercial company with a U.S. launch underway, a major positive driver.

    This is the single biggest new event of the period and the main reason SRRK is moving.

  • Regulatory path cleared in U.S., Europe, Japan Scholar Rock removed a problem fill-finish plant from its application, kept its FDA decision date, and got Japan's OK that no extra trials are needed. Europe will be resubmitted. This lowers the risk of delays and opens more markets.

    It explains why the approval came through and how the company can sell the drug beyond the U.S.

  • Analyst downgrade and price-target split after approval Barclays downgraded SRRK to Equal Weight, saying the approval was already priced in and the non-SMA pipeline needs more proof. Other firms raised targets into the $70s-$80s. This tug-of-war explains recent share swings.

    It is the main counterweight to the good news and shows why the stock fell even after approval.

  • Commercial launch and pricing underway Isembyld is shipping, with a patient support program for insurance and infusions. Announced pricing slightly beat analyst estimates. Early sales execution will now drive the stock more than approval headlines.

    It shows the next phase for SRRK: turning approval into actual revenue.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

August 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.